Salofalk 250mg 10 suppositories — Made in Germany — Free Delivery

Rectal suppositories "Salofalk" are used to treat exacerbations and prevent recurrence of ulcerative colitis limited to the rectum.

The active ingredient is mesalazine (1 suppository contains 250 mg of mesalazine (5-aminosalicylic acid)).

The excipient is solid fat.

Hypersensitivity to mesalazine, to any of the preparations components or to salicylates, gastric ulcer and duodenal ulcer in the acute stage, severe hepatic and / or renal failure, hemorrhagic diathesis.

The preparation is intended for rectal administration.

Treatment of exacerbations of ulcerative colitis (adults): 2 suppositories "Salofalk" 250 mg are injected into the rectum 3 times a day (equivalent to 1500 mg of mesalazine per day).

Prevention of relapse of ulcerative colitis (adults): 1 suppository "Salofalk" 250 mg 3 times a day (equivalent to 750 mg of mesalazine per day).

General dosage instructions: when Salofalk suppositories are intended for use 3 times a day, they are injected into the rectum in the morning, afternoon and evening. The desired therapeutic result can be achieved only with regular and constant use of the preparation "Salofalk". Usually, flare-ups of ulcerative colitis subside within 8-12 weeks. The duration of use is determined by the doctor.

Suppositories "Salofalk" should be taken during pregnancy only when the expected benefit outweighs the potential risk.

This preparation should be used during breastfeeding only when the expected benefit to the mother outweighs the possible risk to the baby. If the baby develops diarrhea, breastfeeding should be stopped.

There is insufficient data on the use of this preparation in children.

No effect on the ability to drive or operate machinery was observed. In cases where dizziness is observed during treatment, you should refrain from driving and working with mechanisms.

So far, no cases of intoxication and specific antidotes have been reported. There are data on cases of overdose (for example, willful suicide with a high oral dose of mesalazine), which do not indicate renal or hepatic toxicity. There is no specific antidote; treatment should be symptomatic and supportive. If necessary, electrolyte infusion (forced diuresis) is used.

Nervous system: rare (≥ 1/10 000; <1/1000) - headache, dizziness.

Cardiovascular system: rare (≥ 1/10 000; <1/1000) - myocarditis, pericarditis.

Gastrointestinal tract: rare (≥ 1/10 000; <1/1000) - abdominal pain, diarrhea, flatulence, nausea and vomiting.

Store in its original packaging to protect from light at a temperature not exceeding 30 ° C, out of the reach of children.

Shelf life is 3 years.